Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pvs230D1-EPA (National Institute of Allergy and Infectious Diseases)
- Development stage
- Unknown
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Pvs230D1-EPA is a transmission-blocking vaccine (TBV) candidate for *Plasmodium vivax* malaria. It consists of the recombinant domain 1 of the *P. vivax* sexual-stage antigen Pvs230 (Pvs230D1), expressed in *Pichia pastoris*, chemically conjugated to recombinant, non-toxic *Pseudomonas aeruginosa* ExoProtein A (rEPA) as a carrier protein to enhance its immunogenicity. Pvs230 is expressed on the surface of gametocytes in the human host and displayed on gametes in the mosquito host. Antibodies generated against Pvs230 disrupt parasite development within the mosquito midgut, thereby blocking transmission. Developed by the Laboratory of Malaria Immunology and Vaccinology (LMIV) at the National Institute of Allergy and Infectious Diseases (NIAID), Pvs230D1-EPA is formulated with the Matrix-M adjuvant and has been evaluated in Phase 1 clinical trials.
- Other names
- Pvs230D1-EPAPvs-230D1-EPAPvs 230D1-EPAPvs230D1-EPA conjugatePvs-230D1-EPA conjugatePvs 230D1-EPA conjugatePvs230D1-eicosapentaenoic acid conjugatePvs-230D1-eicosapentaenoic acid conjugatePvs 230D1-eicosapentaenoic acid conjugate
Beyond the preview
Go deeper on Pvs230D1-EPA (National Institute of Allergy and Infectious Diseases).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pvs230D1-EPA (National Institute of Allergy and Infectious Diseases).